I[ntroduction]{.smallcaps} {#sec1-1}
==========================

Colorectal carcinoma (CRC) is the fourth most common malignancy worldwide, and the disease burden of CRC continues to increase.\[[@ref1]\] Around 40% of the patients presented with colorectal liver metastasis (CRCLM) at their initial diagnosis. Surgical resection is considered the golden standard in the treatment of CRCLM, with 5-year overall survival (OS) rate ranging from 27% to 58%.\[[@ref2][@ref3]\] Nevertheless, only 10--25% of patients with CRCLM are eligible for surgical resection in terms of the extent location of the disease and concurrent medical conditions.\[[@ref2][@ref3]\] Several alternative locoregional therapies including the radiofrequency ablation (RFA), percutaneous ethanol injection, acetic acid injection, microwave coagulation, and transcatheter arterial chemoembolization have been developed. Among these alternative treatments, RFA, which is featured with simplicity, safety, and minimally invasive, is frequently used.

The therapeutic role of RFA gains has been well established in the management of hepatocellular carcinoma (HCC) at early or intermediate stages. Controversial results comparing the therapeutic value of RFA and liver resection (LR) in colorectal cancer liver metastasis (CRCLM) have been reported. Despite the large number of patients treated by RFA worldwide, a randomized study comparing this approach with surgery has not been performed yet. Wenget al.\[[@ref4]\] and Wu *et al*.\[[@ref5]\] have reported their meta-analysis results that LR was superior to RFA in the treatment of patients with CRCLM. In recent years, several new comparative studies have been reported. The relevant clinical evidences have increased. Therefore, it is essential for us to search the available articles and perform the updated meta-analysis comparing the efficacy and safety of LR and RFA in the management of CRCLM.

M[ethods]{.smallcaps} {#sec1-2}
=====================

Literature search {#sec2-1}
-----------------

A literature search of the online databases including PubMed (Medline), EMBASE, Cochrane Library, and Web of Science was performed for all studies up to April 2016. The search algorithm included the following words: "Radiofrequency ablation" (e.g., "radio frequency ablation," "radio-frequency ablation" "RFA"), "'resection" (e.g., "hepatectomy"), "colorectal" (e.g., "colon" and "rectal"), "cancer" (e.g., "tumor"), and liver metastasis (e.g., "liver metastases"). Only studies published in English were selected. Reference lists of all the retrieved articles were manually searched for potentially related articles.

Inclusion criteria {#sec2-2}
------------------

The following criteria were fulfilled for the studies included in the meta-analysis: (1) the studies comparing the clinical outcomes of RFA and LR in the treatment of colorectal cancer liver metastases; (2) the studies reporting at least 3- or 5-year OS and (or) 3- or 5-year disease-free survival (DFS) of each treatment group; and (3) if more than one studies were reported by the same research, only the most recent one with the most comprehensive information was included.

Exclusion criteria {#sec2-3}
------------------

The following studies (cohorts) were excluded from the study: (1) the original studies which did not report the comparative results about the therapeutic value of RFA and LR; (2) those published in the form of review articles, letters, comments, and case reports.

Quality assessment {#sec2-4}
------------------

The quality assessment of the primary studies was carried out using the Newcastle-Ottawa Scale (NOS). Two authors (Yue Han and Dong Yan) performed the study quality assessment independently. When discrepancy occurred, a third author (Xiao Li) was referred. Studies with NOS ≥6 were considered to be of high quality.

Data extraction {#sec2-5}
---------------

Data extraction was performed independently by Yue Han and Dong Yan, and in the case of discrepancy, the decision was made by discussion with a third author (Xiao Li). The main extracted data included: (1) the first author, the year of publication, sample size, study location, and study design; (2) the baseline oncological characteristics of patients including the tumor number, tumor size, and lymph node metastasis; and (3) the outcome of the trials including the OS and DFS at 3 and 5 years as well as the mortality and/or morbidity.

Statistical analysis {#sec2-6}
--------------------

Calculation for dichotomous variables was carried out using the risk ratio (*RR*) and their 95% confidence interval (*CI*) as the summary statistic. Interstudy heterogeneity among the included studies was evaluated by the *I*^2^ statistics.\[[@ref6]\] Time-to-event data including the 3-year OS, 3-year progression-free survival (PFS), 5-year OS, and the 5-year PFS were extracted from individual trials. Pooled categorical comparisons were made by Chi-squared test. If the *I*^2^ was larger than 50%, implying significant statistical heterogeneity between studies, the random effects (DerSimonian-Laird method) model was adopted; in the presence of no observable interstudy heterogeneity (*I*^2^ \< 50%), the fixed-effect model was applied. Two-sided *P* \< 0.05 was considered statistically significant. Sensitivity analysis was performed to evaluate the stability of the results. Each study involved in the meta-analysis was removed each time to reflect the influence of the individual data set on the pooled effects. Evidence of publication bias was evaluated using the Begg\'s test\[[@ref7]\] and Egger\'s test.\[[@ref8]\] All analyses were performed using STATA statistical software package version 12.0 (STATA Corp., College Station, Texas, USA).

R[esults]{.smallcaps} {#sec1-3}
=====================

Description of the enrolled studies {#sec2-7}
-----------------------------------

Three studies\[[@ref9][@ref10][@ref11]\] were from the same medical center, the latest one with the most comprehensive information\[[@ref11]\] was enrolled. Thus, a total of 14 studies\[[@ref3][@ref11][@ref12][@ref13][@ref14][@ref15][@ref16][@ref17][@ref18][@ref19][@ref20][@ref21][@ref22][@ref23]\] with sample size ranging from 29 to 455 have been enrolled \[[Figure 1](#F1){ref-type="fig"}\]. Of them, 1466 patients underwent LR and 739 patients underwent RFA. The detailed information of the included studies was summarized in [Table 1](#T1){ref-type="table"}. NOS was not less than 6 in 12 of the studies.

![The flowchart describing the selection of the literature. RFA: Radiofrequency ablation; LR: Liver resection.](CMJ-129-2983-g001){#F1}

###### 

Baseline characteristics of included studies

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author          Year     Design                Study period           Study location   Treatment          Sample size (male/female)   Age (years)     Tumor size (cm)        Tumor number   Tumor stage (I and II versus III and IV)   LN (+/−)   NOS
  --------------- -------- --------------------- ---------------------- ---------------- ------------------ --------------------------- --------------- ---------------------- -------------- ------------------------------------------ ---------- -----
  Oshowo          2003     Retro                 Not reported           UK               LR                 10/10                       63 (52--77)\*   4 (2--7)\*             1                                                                    5

  RFA Perc        11/14    57 (34--80)\*         3 (1--10)\*            1                                                                                                                                                                           

  Evrard          2004     Retro                 2000--2002             France           LR                 10/7                        57 (25--88)\*   2.2                    1 (1--5)\*                                                           5

  RFA Open        19/14    66 (21--82)\*         1                      3 (1--8)\*                                                                                                                                                                  

  Abdalla         2006     Retro                 1992--2002             USA              LR                 190                         60 (23--88)\*   2.5                                                                                         7

  RFA Open        57       60 (23--88)\*         2.5                    1 (1--8)\*                                                                                                                                                                  

  White           2007     Retro                 1992--2002             USA              LR                 20/10                       62 (42--81)\*   2.7 ± 1.1^‡^           1                                                         17/13      6

  RFA Perc        8/15     62 (48--77)\*         2.4 ± 1.0^‡^           1                                   11/11                                                                                                                                   

  Gleisner        2008     Retro                 1999--2006             USA              LR                 121/71                      61              3.5 (2.0--5.0)\*       1.0--2.5       28/164                                     122/70     6

  RFA Perc        7/4      60                    2.5 (1.9--4.0)\*       1                0/11               7/4                                                                                                                                     

  Berber          2008     Retro                 1996--2007             USA              LR                 57/33                       64              3.8 ± 0.2^‡^           1                                                                    6

  RFA Open        43/25    64                    3.7 ± 0.2^‡^           1                                                                                                                                                                           

  Her             2009     Retro                 1999--2005             Korea            LR                 27/15                                       2.6 (0.6--8.0)\*       1              2/40                                       26/16      6

  RFA Open/Perc   15/10                          2.5 (0.8--3.6)\*       1                1/24               18/7                                                                                                                                    

  Reuter          2009     Retro                 1995--2007             USA              LR                 69/57                       61.9            5.3                    Mean: 2.1      26/100                                                6

  RFA             46/20    63.5                  3.2                    2.8              14/52                                                                                                                                                      

  Mckay           2009     Retro                 1998--2007             Canada           LR                 29/29                       67 (28--83)\*   4.1 (1.5--14.5)\*      1 (1--7)\*                                                           6

  RFA Open/Perc   25/18    67 (37--83)\*         3.0 (1--7.5)\*         2 (1--6)\*                                                                                                                                                                  

  Otto            2009     Prosp                 2002--2008             Germany          LR                 49/33                       62 (38--80)\*   5 (1--15)\*            2 (1--11)\*    11/71                                      11/71      7

  RFA Perc        20/8     64 (42--78)\*         2 (1--5)\*             2 (1--5)\*       4/24               22/60                                                                                                                                   

  Kim             2011     Retro                 1995--2009             Korea            LR                 168/110                     57.1            2.6 ± 2.0^‡^           1.5                                                                  6

  RFA Open/Perc   121/56   60.4                  2.1 ± 1.0^‡^           1.6                                                                                                                                                                         

  Ko              2014     Retro                 2004--2009             Korea            LR                 7/10                        ≤65:4 \>65:8    3.59 (1.60--4.90)^†^                  I--III: 8 IV: 4                            9/3        6

  RFA             4/8      ≤65:12 \>65:5         2.02 (0.80--4.60)^†^                    I--III: 13 IV: 4   11/6                                                                                                                                    

  Tanis           2014     Retro                 2000--2006             Europe           LR                 58/23                       61 (29--77)\*                          1 (1--4)\*                                                           6

  RFA             33/22    64 (39--79)\*         3.0 (1.0--3.9)\*       4 (1--9)\*                                                                                                                                                                  

  Lee             2015     Retro                 2000--2009             Korea            LR                 73/29                       60 (3--79)\*    1.7 (0.2--3.0)\*       Single: 63\                                               30/72      6
                                                                                                                                                                               Multiple: 39                                                         

  RFA Open        35/16    58.5 (35.0--79.0)\*   1.8 (1.0--3.0)\*       Single: 29\                         13/38                                                                                                                                   
                                                                        Multiple: 22                                                                                                                                                                
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Median (range); ^†^Mean (range); ^‡^Mean ± SD. SD: Standard deviation; Retro: Retrospective study; Prosp: Prospective study not random; LR: Hepatic resection; RFA: Radiofrequency ablation; Perc: Percutaneous; Open/Perc: Contains data from both open and percutaneous surgery; LN: Lymph node metastasis; NOS: Newcastle--Ottawa Scale.

Overall survival {#sec2-8}
----------------

With observable interstudy heterogeneity, patients in the RFA group had inferior 3-year OS (*RR*: 1.466, 95% *CI*: 1.218--1.765, *P* \< 0.001, *P* value of *Q*-test for heterogeneity test \[*P*~h~\]: 0.013) \[[Figure 2a](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\] and 5-year OS (RR: 1.361, 95% CI: 1.163--1.593, *P* \< 0.001, *P*~h~ \< 0.001) \[[Figure 2c](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\] when compared with patients in the LR group. Moreover, majority of the subgroup analyses showed that the LR group had better long-term survival than RFA group in terms of 3-year OS \[[Table 2](#T2){ref-type="table"}\].

![Pooled analysis comparing the survival rate between patients in the liver resection and radiofrequency ablation groups. (a) Pooled analysis comparing the 3-year overall survival rate. (b) Pooled analysis comparing the 3-year progression-free survival rate. (c) Pooled analysis comparing the 5-year overall survival rate. (d) Pooled analysis comparing the 5-year progression-free survival rate. Horizontal lines correspond to the study-specific risk ratio and 95% *CI*, respectively. The size of the squares reflects the study-specific weight. The diamond represents the results for the pooled risk ratio and 95% *CI*. *RR*: Risk ratio; *CI*: Confidence interval.](CMJ-129-2983-g002){#F2}

###### 

Main results of the meta-analysis

  Analysis                            OS   PFS                                                                                                                 
  ----------------------------------- ---- ------------------------- --------- ------ --------- ------- ---- ---------------------- --------- ------ --------- -------
  3-year                              12   1.466 (1.218--1.765)      \<0.001   54.0   0.013             10   1.344 (1.196--1.510)   \<0.001   61.9   0.005     
   Subgroup 1                                                                                                                                                  
    Intraoperative                    5    1.733 (1.306--2.300)      \<0.001   62.1   0.032     0.415   5    1.347 (1.223--1.485)   \<0.001   25.3   0.253     0.023
    Percutaneous                      3    0.900 (0.597--1.357)      0.616     0      0.807             2    1.601 (1.133--2.262)   0.008     61.2   0.108     
    Both                              4    1.338 (1.133--1.580)      0.001     0      0.498             3    1.127 (1.011--1.257)   0.031     10.4   0.328     
   Subgroup 2                                                                                                                                                  
    Size of liver metastasis \<3 cm   3    1.380 (0.886--2.149)      0.154     0      0.957             3    1.365 (1.065--1.750)   0.014     0      0.590     
    Size of liver metastasis \<5 cm   3    1.492 (1.066--2.089)      0.020     0      0.527             3    1.393 (1.061--1.830)   0.017     64.2   0.061     
   Subgroup 3                                                                                                                                                  
    Asian                             1    1.407 (0.870--2.277)      0.164     --     --        0.909   1    1.286 (1.002--1.650)   0.048     --     --        0.813
    Caucasian                         11   1.468 (1.200--1.796)      \<0.001   58.2   0.008             9    1.354 (1.189--1.541)   \<0.001   66.2   0.003     
   Subgroup 4                                                                                                                                                  
    Sample size ≥100                  9    1.529 (1.238--1.887)      \<0.001   63.7   0.005     0.287   8    1.298 (1.162--1.451)   \<0.001   60.0   0.014     0.065
    Sample size \<100                 3    1.123 (0.732--1.722)      0.596     0      0.847             2    2.060 (1.423--2.983)   \<0.001   0      0.658     
  5-year                              13   1.361 (1.163--1.593)      \<0.001   73.2   \<0.001           11   1.396 (1.230--1.584)   \<0.001   81.2   \<0.001   
   Subgroup 1                                                                                                                                                  
    Intraoperative                    5    1.309 (1.005--1.706)      0.046     83.3   \<0.001   0.347   5    1.395 (1.239--1.571)   \<0.001   67.6   0.015     0.395
    Percutaneous                      4    1.229 (0.951--1.588)      0.115     0      0.605             3    1.276 (1.089--1.497)   0.003     32.6   0.227     
    Both                              4    1.534 (1.107--2.126)      0.010     83.0   0.001             3    1.669 (0.981--2.841)   0.059     94.5   \<0.001   
   Subgroup 2                                                                                                                                                  
    Size of liver metastasis \<3 cm   5    1.395 (0.884--2.201)      0.153     76.8   0.002             5    1.282 (0.896--1.834)   0.174     66.8   0.017     
    Size of liver metastasis \<5 cm   4    1.638 (1.035--2.591)      0.035     74.4   0.008             4    1.468 (1.108--1.945)   0.008     80.8   0.001     
   Subgroup 3                                                                                                                                                  
    Asian                             2    1.238 (0.899--1.705)      0.191     22.3   0.257     0.851   2    1.226 (1.012--1.484)   0.037     0      0.552     0.345
    Caucasian                         11   1.370 (1.154--1.626)      \<0.001   77.0   \<0.001           9    1.437 (1.245--1.658)   \<0.001   84.5   \<0.001   
   Subgroup 4                                                                                                                                                  
    Sample size ≥100                  9    1.359 (1.125--1.640)      0.001     81.1   \<0.001   0.937   8    1.387 (1.206--1.595)   \<0.001   85.8   \<0.001   0.825
    Sample size \<100                 4    1.390 (1.083--1.785)      0.010     0      0.564             3    1.489 (0.968--2.290)   0.070     60.5   0.079     
    Morbidity of all studies          9    0.494 (0.280--0.873)^a^   0.015     81.5   \<0.001                                                                  

a: Odds ratio; OS: Overall survival; PFS: Progression--free survival; *N*: Number; *HR*: Hazard ratio; *Ph*: *P* value of Q test for heterogeneity test; *Pr*: *P* value of meta regression analysis.

Disease-free survival {#sec2-9}
---------------------

Patients in the RFA group gained significantly shorter 3-year PFS (RR: 1.344, 95% CI: 1.196--1.510, *P* \< 0.001, *P*~h~= 0.005) \[[Figure 2b](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\] and 5-year PFS (RR: 1.396, 95% CI: 1.230--1.584, *P* \< 0.001, *P*~h~ \< 0.001) \[[Figure 2d](#F2){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\] than those of patients in the LR group. The significantly higher DFS rates in LR group were also observed in majority of the subgroups \[[Table 2](#T2){ref-type="table"}\].

Safety {#sec2-10}
------

Nine of the included studies compared the morbidities between the RFA group and LR group. The incidence of postoperative morbidity was significantly lower in the RFA group than that in the LR group (odds ratio: 0.494, 95% CI: 0.280--0.873, *P* = 0.015, *P*~h~ \< 0.001) \[[Figure 3](#F3){ref-type="fig"} and [Table 2](#T2){ref-type="table"}\].

![Pooled analysis comparing the morbidity rate of patients in the liver resection and radiofrequency ablation groups. Random effects model was used. Horizontal lines correspond to the study-specific hazard ratio and 95% *CI*, respectively. The size of the squares reflects the study-specific weight. The diamond represents the results for the pooled risk ratio and 95% *CI*. *RR*: Risk ratio; *CI*: Confidence interval.](CMJ-129-2983-g003){#F3}

Sensitivity analyses {#sec2-11}
--------------------

A single primary study was removed at a time to test its influence on the overall results. The pooled analyses of the rest studies agreed with the overall results \[[Figure 4](#F4){ref-type="fig"}\].

![Sensitivity analyses of the survival and morbidity rate comparisons between patients in the liver resection and radiofrequency ablation groups. (a) Sensitivity analysis of the 3-year overall survival rate comparison. (b) Sensitivity analysis of the 3-year progression-free survival rate comparison. (c) Sensitivity analysis of the 5-year overall survival rate comparison. (d) Sensitivity analysis of the 5-year progression-free survival rate comparison. (e) Sensitivity analysis of the morbidity rate comparison. A single study was removed at a time, and the pooled estimation of the remaining studies was performed. *CI*: Confidence interval.](CMJ-129-2983-g004){#F4}

Publication bias {#sec2-12}
----------------

The funnel plot did not show significant asymmetry by Begg\'s test in 3-year survival \[*P*~r~ \> \|*z*\| = 0.945, [Figure 5a](#F5){ref-type="fig"}\], 5-year OS \[*P*~r~ \> \|*z*\| = 0.360, [Figure 5b](#F5){ref-type="fig"}\], 3-year DFS \[*P*~r~ \> \|*z*\| = 0.592, [Figure 5c](#F5){ref-type="fig"}\], 5-year DFS \[*P*~r~ \> \|*z*\| = 0.533, [Figure 5d](#F5){ref-type="fig"}\], and morbidity rates \[*P*~r~ \> \|*z*\| = 0.466, [Figure 5e](#F5){ref-type="fig"}\].

![Funnel plot describing the comparative analysis of survival and morbidity rates between patients in the liver resection and radiofrequency ablation groups. (a) Funnel plot describing the comparative analysis of 3-year overall survival rate. (b) Funnel plot describing the comparative analysis of 3-year progression-free survival rate. (c) Funnel plot describing the comparative analysis of 5-year overall survival rate. (d) Funnel plot describing the comparative analysis of 5-year progression-free survival rate. (e) Funnel plot describing the comparative analysis of morbidity rate. *RR*: Risk ratio.](CMJ-129-2983-g005){#F5}

D[iscussion]{.smallcaps} {#sec1-4}
========================

In the present meta-analysis, we found that patients with CRCLM who were treated by LR gained better survival outcomes than those who were treated by RFA. However, RFA outperformed LR in terms of fewer perioperative morbidity rates.

Surgical resection is considered to be the first-line treatment for the local control of CRCLM. However, hepatectomy is not always possible due to large tumor size, anatomic location, and poor health status. RFA, which has the advantages of minimal invasiveness, might be favorable for the local control of CRCLM.\[[@ref24]\] Besides, with the advances in the imaging-guided location, artificial hydrothorax, and the probes, the indications for RFA have been greatly expanded. Nevertheless, there has been no consensus on whether RFA can get the similar therapeutic value as that of LR.

The inferior survival outcomes of RFA could be explained in several aspects. First, RFA patients were more likely to recur near the RFA site due to incomplete ablation of lesion size, heat sink effect, or limitations of the technique.\[[@ref25][@ref26]\] The underlying molecular mechanism explaining the higher recurrence rates and inferior survival outcome remains to be resolved. Yoshida *et al*.\[[@ref26]\] found that sublethal heat treatment skewed HCC cells toward epithelial-mesenchymal transition and transformed them to a progenitor-like, highly proliferative cellular phenotype *in vitro* and *in vivo*, which was driven significantly by p46-Src homology and collagen and downstream extracellular signal-related kinase 1/2. Second, in many medical institutions, the patients who underwent RFA were those who were not eligible for surgery because of poor health condition, inadequate liver function reserve, or extensive tumor burden. Third, the resection allows in-depth intraoperative exploration and pathological evaluation as well. More comprehensive evaluation of the tumor status may be beneficial for the design of treatment strategies.

Subgroup analyses showed that in patients with tumor size \<3 cm, the survival outcomes of RFA and LR were identical. Recently, the American Society of Clinical Oncology performed an evidence review for RFA on both resectable and unresectable CRCLMs.\[[@ref15]\] They found that patients with liver lesion measuring \<3 cm had a high ablation success rate and the best outcome. For larger tumors, to achieve the safe margin, the RFA needle needs to be repositioned for multiple ablation zones, which will increase the chance of an incomplete ablation and the risk for a local recurrence.

Heterogeneity remained to be a concern in our meta-analysis. We conducted the meta-regression analysis based on the RFA method, sample size, and study region. These factors failed to explain the source of heterogeneity. Only in the pooled analysis for 5-year PFS, RFA method accounted for part of the heterogeneity. We surmised that the heterogeneity of the included studies might be caused by the heterogeneity in the study design, patients' baseline characteristics, follow-up duration, and so on. Further, high-quality randomized controlled trails (RCTs) are needed to resolve this problem.

A well-designed RCT may provide more convincing data about the strengths and shortcomings of RFA and LR in the treatments of CRCLM. Nevertheless, no results from the RCT have been published yet. This issue can be explained by several reasons. One factor may be the reluctance of patients to be randomly assigned. Some patients prefer to undergo surgical operation rather than RFA. Another factor is surely the objective difficulty in balancing the clinicopathological features, including stage of disease, size, and number of liver metastasis, presence or absence of extrahepatic disease, types of previous, concomitant, or salvage chemotherapies, and primary and secondary end points between the two arms. Moreover, many clinicians may be reluctant to enroll patients into trials because they are convinced that the currently available data from highly selected patient series provide sufficient evidence. Finally, the huge economic costs of performing the RCT may represent a further obstacle.

Admittedly, there are several limitations in our study. First of all, majority of the enrolled studies were retrospectively performed, which were susceptible to several biases. Second, heterogeneity was remarkable in our meta-analysis. Heterogeneity might exist in the age, sample size, study region, tumor stage, liver function reserve, and history of previous treatments of the patients. Moreover, the clinicopathological features of patients in the RFA groups might not be comparable to that of patients in the LR group. Third, it is indeed quite important to analyze the influence of chemotherapy and some other therapies on the prognosis. To our regret, only one study provided us with the survival outcome with respect to whether the patients underwent chemotherapies. Moreover, the detailed cycles, regiments, and the other therapies were not homogeneous. We hope that future randomized controlled studies may resolve this problem and provide us with much more sound clinical evidences. Finally, publication bias remains to be a main concern. Articles with negative results were much more difficult to be favored.\[[@ref8]\] Thus, the present results may be overvalued to some extent.\[[@ref8]\] In addition, although we tried our best to identify as more relevant articles as possible, we only searched articles written in English in a limited number of online databases. The included number of studies may be somehow insufficient.

In conclusion, CRCLM patients who underwent LR gained better clinical outcomes compared with those of patients who underwent RFA. Meanwhile, the advantages of RFA including lower morbidity should be noted. More well-designed RCTs should be performed before we finally arrive at a rational comprehension about the therapeutic value of the two treatment options.
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